Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Cancer Letters|November 29, 2020
Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastomaPaola Infante, Alessio Malfanti, Deborah Quaglio, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 8, 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressantMaurizio Fava, Stephen M Stahl, Sara De Martin, et al.
International Clinical Psychopharmacology|February 27, 2026
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressantsClotilde Guidetti, George I Papakostas, Steven Stahl, et al.
Cancer Research|January 4, 2024
Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial CarcinomaSana Hosni, Viola Kilian, Niklas Klümper, et al.
The Journal of Clinical Psychiatry|February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label StudyMaurizio Fava, Luca Pani, Sara De Martin, et al.
Drug Delivery and Translational Research|December 16, 2025
Functional and therapeutic effects of Glabrescione B delivery by liposomes on Hedgehog-dependent tumorsPaola Infante, Raffaella Daniele, Marta Bottero, et al.
The American Journal of Psychiatry|December 22, 2021
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind TrialMaurizio Fava, Stephen Stahl, Luca Pani, et al.
The Journal of Clinical Psychiatry|June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled TrialMaurizio Fava, Stephen M Stahl, Luca Pani, et al.
Brain : a Journal of Neurology|July 15, 2025
Oxytocin seals the blood-brain barrier, improving 22q11.2 deletion syndrome trajectoriesGiulia Castellani, Mariasole Ciampoli, Arianna Benedetti, et al.
Pharmacological Research|December 31, 2025
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and Type 2 Diabetes via 5-HT2B receptor-dependent mechanismsMartina Colognesi, Daniela Gabbia, Anna Signor, et al.
Pageof 10